← Back to Screener
Genelux Corporation Common Stock (GNLX)
Price$2.65
Favorite Metrics
Price vs S&P 500 (26W)-53.72%
Price vs S&P 500 (4W)6.76%
Market Capitalization$125.01M
All Metrics
Book Value / Share (Quarterly)$0.49
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.64
Price vs S&P 500 (YTD)-40.15%
Net Profit Margin (TTM)-98125.00%
EPS (TTM)$-0.88
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.88
EPS (Annual)$-0.95
ROI (Annual)-113.68%
Cash / Share (Quarterly)$0.56
ROA (Last FY)-86.04%
EBITD / Share (TTM)$-0.91
Operating Margin (TTM)-101500.00%
Cash Flow / Share (Annual)$-0.63
P/B Ratio6.72x
P/B Ratio (Quarterly)8.53x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-6.59x
ROA (TTM)-97.37%
EPS Incl Extra (Annual)$-0.95
Current Ratio (Annual)4.57x
Quick Ratio (Quarterly)4.08x
3-Month Avg Trading Volume0.23M
52-Week Price Return8.56%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.92
P/S Ratio (Annual)15626.03x
Asset Turnover (Annual)0.00x
52-Week High$8.54
EPS Excl Extra (Annual)$-0.95
CapEx CAGR (5Y)-26.45%
26-Week Price Return-44.97%
Quick Ratio (Annual)4.48x
13-Week Price Return6.90%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.20x
Enterprise Value$120.316
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-373362.50%
Cash / Share (Annual)$0.90
3-Month Return Std Dev64.30%
Net Income / Employee (TTM)$-1
ROE (Last FY)-113.68%
Net Interest Coverage (Annual)-4.74x
EPS Basic Excl Extra (Annual)$-0.95
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.88
ROI (TTM)-129.29%
P/S Ratio (TTM)15626.03x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-1.46
Price vs S&P 500 (52W)-26.53%
Year-to-Date Return-36.01%
5-Day Price Return10.28%
EPS Normalized (Annual)$-0.95
ROA (5Y Avg)-116.11%
Net Profit Margin (Annual)-373362.50%
Month-to-Date Return15.29%
Cash Flow / Share (TTM)$-1.00
EBITD / Share (Annual)$-0.99
Operating Margin (Annual)-391575.00%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.88
P/TBV (Quarterly)12.34x
P/B Ratio (Annual)3.10x
Pretax Margin (TTM)-98125.00%
Book Value / Share (Annual)$0.77
Price vs S&P 500 (13W)4.03%
Beta0.55x
Revenue / Share (TTM)$0.00
ROE (TTM)-129.29%
52-Week Low$2.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.08
4.08
4.08
4.08
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GNLXGenelux Corporation Common Stock | 15626.03x | — | — | — | $2.65 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Genelux Corp is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for difficult-to-treat solid tumors. The company's lead candidate, olvimulogene nanivacirepvec (Olvi-Vec), is being evaluated for lung and pancreatic cancers. The approach leverages engineered viruses to activate the patient's immune system against cancer cells.